NDAORALTABLET
Approved
May 1942
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
5/8 — Partial
PREMARIN (estrogens, conjugated) by Pfizer is estrogen receptor agonists [moa]. Approved for moderate to severe vasomotor symptoms due to menopause, moderate to severe vulvar, vaginal atrophy due to menopause () and 10 more indications. First approved in 1942.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREMARIN is a conjugated estrogen oral tablet indicated for moderate-to-severe vasomotor symptoms, vulvar/vaginal atrophy, hypoestrogenism, osteoporosis, and palliative treatment of select cancers. It functions as an estrogen receptor agonist, binding to nuclear estrogen receptors to modulate gonadotropin secretion and reduce menopausal symptoms. The product has been marketed since 1942 and remains a foundational hormone replacement therapy.
LOE Approaching
As a legacy product approaching loss of exclusivity, PREMARIN teams face competitive pricing pressure and potential downsizing; career growth opportunities are limited without successful lifecycle extension strategies.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Worked on PREMARIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.